Key Takeaways TLRY rose 44.1% on Friday after reports that an executive order could reclassify marijuana under federal law.Tilray Brands rallied as the reclassification could ease banking limits, tax burdens and investment barriers.Before the surge, TLRY was down 36.6% YTD, highlighting how quickly sentiment shifts on reform signals.Shares of cannabis producer Tilray Brands, Inc. (TLRY) surged 44.1% on Friday, Dec. 12, 2025, on reports that President Donald Trump is expected to sign an executive order as ea ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Cronos Group (CRON) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Cronos Group is a member of our Medical group, which includes 947 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector ...

It has been about a month since the last earnings report for Ironwood Pharmaceuticals (IRWD) . Shares have added about 24.9% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Ironwood due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for Ironwood Pharmaceuticals, Inc. before we dive into how investors and analysts have reacted as of late ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aurinia Pharmaceuticals (AUPH) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Aurinia Pharmaceuticals is one of 947 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks S ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Alpha Cognition Inc. (ACOG) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Alpha Cognition Inc. is a member of the Medical sector. This group includes 950 individual stocks and currently holds a Zacks Sector R ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Guardant Health (GH) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Guardant Health is a member of our Medical group, which includes 950 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, m ...

Core Viewpoint - Collegium Pharmaceutical (COLL) has demonstrated strong stock performance, with a 33.5% increase over the past month and a 67% gain since the beginning of the year, significantly outperforming the Zacks Medical sector and the Zacks Medical - Drugs industry [1][2]. Financial Performance - The company has consistently exceeded earnings expectations, reporting an EPS of $2.25 against a consensus estimate of $1.88 in its last earnings report [2]. - For the current fiscal year, Collegium is projected to achieve earnings of $7.55 per share on revenues of $783.93 million, reflecting a 17.05% increase in EPS and a 24.15% increase in revenues [3]. - The following fiscal year is expected to see a slight decline in EPS to $7.4 per share, with revenues increasing to $807.27 million, indicating a year-over-year change of -2.03% in EPS and 2.98% in revenues [3]. Valuation Metrics - Collegium Pharmaceutical's stock trades at a valuation of 6.3X current fiscal year EPS estimates, significantly lower than the peer industry average of 19.3X [7]. - On a trailing cash flow basis, the stock trades at 3.9X compared to the peer group's average of 15.9X, positioning the company favorably for value investors [7]. Zacks Rank and Style Scores - The company holds a Zacks Rank of 1 (Strong Buy), supported by rising earnings estimates [8]. - Collegium has a Value Score of A, a Growth Score of D, and a Momentum Score of C, resulting in a combined VGM Score of B [6][9]. Industry Comparison - The Medical - Drugs industry is performing well, ranking in the top 28% of all industries, providing a favorable environment for both Collegium Pharmaceutical and its peer, Catalyst Pharmaceuticals, Inc. (CPRX) [12]. - Catalyst Pharmaceuticals has a Zacks Rank of 2 (Buy) and has also shown strong earnings performance, beating consensus estimates by 33.33% [10][11].